Compare Abeona Therapeutics Inc (ABEO) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Liberty Global Ltd Class C — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Liberty Global Ltd Class C trades at $10.31 (market cap $3.60B). The key difference: Liberty Global Ltd Class C is far larger — about 9.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| ABEO | LBTYK | |
|---|---|---|
Market Cap | $373.32M | $3.60B |
Sector | Health | Technology |
52-Week High | $7.23 | $12.67 |
52-Week Low | $4.17 | $10.07 |
Enterprise Value | $228.22M | $10.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
LBTYK trades at $10.50, down 3.67% today, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $7.14B in 2025 despite $4.88B revenue, though recent Q1 2026 earnings beat expectations. Analyst sentiment remains positive with 69% buy ratings, while technical indicators show resistance at $11 and support at $10.
The outlook hinges on the planned 2027 Ziggo Group spin-off, which could unlock value, but persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. Near-term catalysts include Q2 2026 results in July, with the stock offering speculative upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
